Recently diagnosed

1. Early Detection of Blood Vessel Abnormalities in Children with Diabetes.  IRB# 034-9000-243. Principal Investigator: Daniel E. Hale, MD (210) 358-7586.

On insulin pump therapy

• No studies at this time, please check back later.

Relatives of type 1 diabetes

• TrailNet: Natural History Study of the Development of Type 1 Diabetes IRB# 20060084H. Principal Investigator: Daniel Hale, MD (210) 704-4351.

Other

• Type 1 Diabetes Genetics Consortium IRB#HSC 20070255H. Principal Investigator: Daniel Hale, MD (210) 704-4351

On diet only

1. Durability of Early Combination Therapy vs. Conventional Therapy in New Onset Diabetes.(within 1 year) #HSC20080456H. Principal Investigator: Ralph De Fronzo, MD - (210) 358-7200.
2. Evaluation of the Metabolic Effects of Excenetide, Rosiglitazone, and Excenatide Plus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus Treated with Metformin. IRB#056-5014-092. Principal Investigator: Ralph De Fronzo, MD - (210) 358-7200. 
    
3. Effect of Exenatide Treatment on Splanchnic Glucose Uptake in Patients with Type 2 Diabetes Mellitus. IRB# 045-5014-041. Principal Investigator: Ralph A DeFronzo, MD-(210) 358-7200.
4. Molecular Mechanisms of Inflammation-Associated Skeletal Muscle Insulin Resistance in Mexican Americans with Type 2 Diabetes. IRB# 045-5014-114. Principal Investigator: Nicolas Musi, MD-(210) 358-7200.

On oral medications

1. Anti-inflammatory Effect of Exercise in Skeletal Muscle: Novel Mechanism to Treat Insulin Resistance. IRB# HSC20060025H. Principal Investigator: Nicolas Musi, MD - (210) 358-7200.
2. Role of TLR4 on Insulin Resistance in Human Muscle. IRB# HSC20080015H. Principal Investigator: Nicolas Musi (210)358-7200
3. Molecular Mechanisms of Inflammation-Associated Skeletal Muscle Insulin Resistance in Mexican Americans with Type 2 Diabetes. IRB# 045-5014-114. Principal Investigator: Nicolas Musi, MD-(210) 358-7200.

On insulin therapy

• No studies at this time, please check back later.

On combination oral/insulin

1. Study of the Improvement of Metabolic Control, Insulin Resistance, Vascular Endothelial Dysfunction and Inflammation in Mexican American Type 2 Diabetic Patients Treated with Basal-Bolus Insulin Glargine-Apidra Comination. IRB# 056-5014-121. Principal Investigator: Eugenio Cersosimo, MD (210) 358-7200.

Exercise

1. Anti-inflammatory Effect of Exercise in Skeletal Muscle: Novel Mechanism to Treat Insulin Resistance. IRB# 056-5014-025 Principal Investigator: Dr. Nicolas Musi-(210) 358-7200.

2. Molecular Mechanisms of Inflammation-Associated Skeletal Muscle Insulin Resistance in Mexican Americans with Type 2 Diabetes. IRB# 045-5014-114. Principal Investigator: Nicolas Musi, MD-(210) 358-7200.

Type 1 diabetes

1. A Phase III, 3-Arm, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus, IRB#HSC20090153H. Principal Investigator: William M. Rogers, MD - 210-704-4443.

2. Early Detection of Blood Vessel Abnormalities in Children with Diabetes. IRB# 034-9000-243. Principal Investigator: Daniel E. Hale, MD (210) 358-7586.

Type 2 diabetes

1. Early Detection of Blood Vessel  Abnormalities in Children with Diabetes. IRB# 034-9000-243. Principal Investigator: Daniel E. Hale, MD (210) 358-7586.

2. Treatment Options for Type 2 Diabetes in Adolescents and Youth Genetics Study. IRB# 20090028H. Principal Investigator: Jane Lynch, MD. 210-358-7550.

Other

1. Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes. IRB#: HSC20080343H, Prinicipal Investigator: Jane Lynch, MD (210) 358-7550.

2. TrailNet: Natural History Study of the Development of Type 1 Diabetes IRB# 20060084H. Principal Investigator: Daniel Hale, MD (210) 358-7586.

3. Type 1 Diabetes Genetics Consortium IRB#HSC 20070255H. Principal Investigator: Daniel Hale, MD (210) 358-7586.

4. The San Antonio Family Assessment of Metabolic Risk Indicators in Youth. IRB# 045-0024-092 No UHS number. Principal Investigator: R. Duggirala (210) 358-7550. Currently recruiting from parents who previously participated in the San Antonio Family Heart Study, the San Antonio Family Diabetes or Gallbladder Study or the Veterans Administration Genetic Epidemiology Study.

5. Early Detection of Blood Vessel  Abnormalities in Children with Diabetes.  IRB# 034-9000-243. Principal Investigator: Daniel E. Hale, MD (210) 358-7586.

6. Prevalence and Progression of Type 2 Diabetes Mellitus in Mexican American Youth. IRB# 990-9000-456. Principal Investigator: Daniel Hale, MD (210) 358-7550.

7. Norditropin in Children with Growth Failure Associated with IGF Deficiency: A 12- month, open-label, Randomized, Parallel Group Study. IRB# 023-9000-148. Principal Investigator: Daniel Hale, MD-(210) 358-7550.

8. The Metabolic Syndrome in Mexican American Children. IRB# 
   045-0024-092. Principal Investigator: Ravindranath Duggirala, PhD - (210) 358-7550. 

Gestational diabetes

• No studies at this time, please check back later.

Family members

1. The San Antonio Family Assessment of Metabolic Risk Indicators in Youth IRB# 045-0024-092 No UHS number. Principal Investigator: R. Duggirala (210) 358-7550. Currently recruiting from parents who previously participated in the San Antonio Family Heart Study, the San Antonio Family Diabetes or Gallbladder Study or the Veterans Administration Genetic Epidemiology Study

2. Effect of Pioglitazone versus Placebo Treatment on the Delay and/or Prevention of Type 2 Diabetes Mellitus in Subjects at High Risk for the Development of the Disease. IRB# 023-5014-209. Principal Investigator: Ralph A DeFronzo, MD-(210) 358-7200.

3. Molecular Epidemiology of Type 2 Diabetes Mellitus in Mexican Americans. IRB# 923-5014-439. Principal Investigator: Ralph A DeFronzo, MD-(210) 358-7200.

Overweight

1. The Role of Inflammatory, Adipocytokines, and Insulin Signaling and Sensitivity in the Prevention of Type 2 Diabetes Mellitus in Hypertensive Subjects Treated with Valsartan. IRB# HSC20070065H. Principal Investigator: Ralph DeFronzo, MD
    
2. Effect of Pioglitazone versus Placebo Treatment on the Delay and/or Prevention of Type 2 Diabetes Mellitus in Subjects at High Risk for the Development of the Disease. IRB# 023-5014-209. Principal Investigator: Ralph A DeFronzo, MD-(210) 358-7200.

Healthy lean subject

1. Role IKK/IKB/NFKB Signaling In Insulin Resistance In Aging Muscle. IRB# HSC20070589H. Principal Investigator: Nicolas Musi (210)358-7200.

2. Anti-inflammatory Effect of Exercise in Skeletal Muscle: Novel Mechanism to Treat Insulin Resistance. IRB# HSC20060025H. Principal Investigator: Nicolas Musi (210)358-7200.

3. Role of TLR4 on Insulin Ressitance in Human Muscle. IRB# HSC20080015H. Principal Investigator: NIcolas Musi (210)358-7200.

Healthy overweight subject

1. Anti-inflammatory Effect of Exercise in Skeletal Muscle: Novel Mechanism to Treat Insulin Resistance. IRB# HSC20060025H. Principal Investigator: Nicolas Musi (210)358-7200.

2. Role of TLR4 on Insulin Ressitance in Human Muscle. IRB# HSC20080015H. Principal Investigator: NIcolas Musi (210)358-7200.

3. Molecular Mechanisms of Inflammation-Associated Skeletal Muscle Insulin Resistance in Mexican Americans with Type 2 Diabetes. IRB# 045-5014-114 . Principal Investigator: Nicolas Musi, MD (210) 358-7200.

Foot problems & neuropathy

• A Randomized, Controlled Trial Examining Cellular Energetics and Oxygenation Levels Related to Various Wound Treatment Therapies. Must have Type II Diabetes and a diabetic foot ulcer on the bottom of the foot. IRB #: HSC20080017H. Principal Investigator: Thomas Zgonis, DPM - (210) 358-7737.

Eye disease

• The Effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus as Assessed by Optical Tomography. #HSC200901334. Principal Investigator: Dr. Eugenio Cersosimo  (210) 358-7200.

Kidney disorders

• No studies at this time, please check back later.

High blood pressure

• The Role of Inflammatory, Adipocytokines, and Insulin Signaling and Sensitivity in the Prevention of Type 2 Diabetes Mellitus in Hypertensive Subjects Treated with Valsartan. IRB# HSC20070065H. Principal Investigator: Dr. Ralph DeFronzo (210) 358-7200.

Lipid (cholesterol) abnormalities

• No studies at this time, please check back later.

Hyperbaric & wound care

• No studies at this time, please check back later.

Gland disorders (thyroid, adrenal, etc.)

1. Norditropin in Children with Growth Failure Associated with IGF Deficiency: A 12- month, open-label, Randomized, Parallel Group Study. IRB# 023-9000-148. Principal Investigator: Daniel Hale, MD-(210) 358-7550.

Osteoporosis

• No studies at this time, please check back later.

Other

• Vitamin D in Youth with Non-Alcoholic Fatty Liver Disease. IRB#: HSC20090257H. Principal Investigator: Carisse Mendoza-Orsi, MD (210) 704-4443.

• Improving Diabetes Risk Factors in Mexican-American Persons with Schizophrenia by Switching to Ziprasidone. IRB# HSC20070052H. Principal Investigator: Ralph De Fronzo (210) 358-7200.